Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene’s BTK Inhibitor Recommended for EU Approval as Lymphocytic Leukemia Therapy

publication date: Oct 14, 2022

Beijing’s BeiGene reported Europe’s CHMP recommended approval of its BTK inhibitor, Brukinsa® (zanubrutinib), for chronic lymphocytic leukemia (CLL). BeiGene says it designed Brukinsa for improved results by optimizing bioavailability, half-life, and selectivity. The CHMP recommendation is based on two global Phase III clinical trials that showed better efficacy and fewer side effects compared to current therapies. BeiGene is conducting 35 Brukinsa trials that have enrolled more than 4,500 subjects. It is approved in various countries for Waldenström's macroglobulinemia, mantle cell lymphoma and marginal zone lymphoma. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160; SHA: 688235)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital